Workflow
郁枢达片
icon
Search documents
一周医药速览(06.23-06.27)
Cai Jing Wang· 2025-06-27 08:43
Group 1 - Xiansheng Pharmaceutical announced that its insomnia treatment drug Daridorexant (brand name: Kewiko®) has been approved for marketing in China, enhancing patient access and supporting long-term use [1] - HAP Pharmaceutical entered a global strategic collaboration with Otsuka Pharmaceutical to develop a BCMAxCD3 bispecific T-cell engager, receiving an upfront payment of $47 million and potential additional payments up to $623 million based on future milestones [1] - Baotai announced a licensing agreement with Stein for the commercialization rights of BAT2406 (Dupilumab) in Latin America, with total upfront and milestone payments potentially reaching $10 million [1] Group 2 - David Medical received a medical device registration certificate for its electric stretcher, which offers significant advantages over traditional manual devices, improving operational efficiency and reducing the burden on healthcare personnel [2] - Hanyu Pharmaceutical's subsidiary received approval for the listing of its active pharmaceutical ingredient Acetate Degarelix, which is used to treat advanced prostate cancer [3] - China Traditional Chinese Medicine reported that its innovative TCM drug Yushudapin's registration application has been accepted, showing significant efficacy in improving early symptoms of depressive disorders [4]
中国中药:国家药监局受理郁枢达片的新药注册上市申请
news flash· 2025-06-25 10:50
Core Viewpoint - The announcement highlights that the application for the innovative traditional Chinese medicine, Yushuda Tablets, has been accepted by the National Medical Products Administration of China, indicating a significant step towards its market introduction [1] Group 1: Product Development - Yushuda Tablets are designed to invigorate the spleen, transform dampness, and regulate qi, showing significant efficacy in alleviating symptoms of emotional distress such as depression [1] - Clinical studies confirm that Yushuda Tablets demonstrate notable effectiveness, particularly in improving early mild to moderate depressive symptoms [1] Group 2: Clinical Trials - The Phase III clinical trial results completed by Tongjitang Pharmaceutical in 2024 indicate that Yushuda Tablets exhibit good safety and efficacy in treating mild to moderate depression [1] - The efficacy of Yushuda Tablets is reported to be significantly superior to that of the placebo group [1]